Not long ago, most patients suspected of having coronary artery
disease were whisked to the hospital for a cardiac catheterization procedure. Today, more
patients than not first have a nuclear cardiology study to see if catheterization is
necessary.
Nuclear cardiology, or single photon emission computed tomography (SPECT), has
become the fastest growing nuclear medicine study out there. Its usefulness accounts for
its increasing popularity, physicians say. But easier access to nuclear cardiology tools
also plays a role. Previously the domain of hospitals, nuclear cardiology gamma cameras
are shifting into cardiology offices, making the procedure more comfortable and efficient
for doctors and patients.
Though not as common as nuclear cardiology, cardiac positron emission tomography,
or cardiac PET, is experiencing even faster growth. Considered the gold standard in
determining cardiac muscle viability, cardiac PET is hampered by its high cost. But more
favorable Medicare reimbursement already is helping PET gain ground, especially in
cardiology offices.
SPECT Popularity
Nuclear medicine was first popular among oncologists looking for tumors in bones
and soft tissues. But about 25 years ago, a new test called myocardial perfusion using
Thallium 201 launched nuclear cardiologys popularity. Doctors now could
noninvasively assess the heart cells physiology to determine whether the muscle was
still viable after a heart attack.
John C. Thomas, marketing manager for nuclear medicine and PET at Siemens Medical
Solutions (Iselin, N.J.), says nuclear cardiology is the only nuclear medicine area still
growing in the United States. Other areas are plateauing or even scaling down in
utilization, while nuclear cardiology has grown at a double-digit rate every year for the
last five years, Thomas says. He estimates that nuclear cardiology scans account for
half of all nuclear medicine scans performed today.
Please refer to the June 2002
issue for the complete story.
For information on article reprints, contact
Martin St. Denis